Phase II Randomized Study of Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical Cystectomy
Condition: Bladder Cancer Interventions: Drug: Olaparib; Drug: Durvalumab Sponsor: Latin American Cooperative Oncology Group Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Bladder Cancer | Cancer | Cancer & Oncology | Carcinoma | Neoadjuvant Therapy | Research | Study